|
| 1 |
|
Conditions listed in this trial |
|
|
Psychotic Disorders |
|
|
Depression |
|
|
Depressive Disorder, Major |
|
| 2 |
|
Additional conditions recognized in this trial |
|
|
Depressive Disorder |
|
|
Disease |
|
| 3 |
|
More general conditions related to this trial |
|
|
Behavioral Symptoms |
|
|
Mental Disorders |
|
|
Mood Disorders |
|
|
Pathologic Processes |
|
|
Schizophrenia and Disorders with Psychotic Features |
|
| 4 |
|
Interventions listed in this trial |
|
|
Mifepristone |
|
| 5 |
|
More general drug interventions related to this trial |
|
|
Abortifacient Agents |
|
|
Abortifacient Agents, Steroidal |
|
|
Contraceptive Agents |
|
|
Contraceptive Agents, Female |
|
|
Contraceptives, Oral |
|
|
Contraceptives, Oral, Synthetic |
|
|
Contraceptives, Postcoital |
|
|
Contraceptives, Postcoital, Synthetic |
|
|
Hormone Antagonists |
|
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
|
Luteolytic Agents |
|
|
Menstruation-Inducing Agents |
|
|
Pharmacologic Actions |
|
|
Physiological Effects of Drugs |
|
|
Reproductive Control Agents |
|
|
Therapeutic Uses |
|
| 6 |
|
Sponsors listed in this trial |
|
|
Stanford University |
|
|
National Institutes of Health (NIH) |
